Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors

被引:68
|
作者
D'Agostino, Ralph B., Sr. [1 ]
Collins, Sylva H. [2 ]
Pencina, Karol M. [1 ]
Kean, Yin
Gorbach, Sherwood [2 ]
机构
[1] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[2] Cubist Pharmaceut, Lexington, MA USA
关键词
Clostridium difficile infection; CDI; fidaxomicin; vancomycin; INTEGRATED DISCRIMINATION; NET RECLASSIFICATION; VANCOMYCIN; EPIDEMIOLOGY; FIDAXOMICIN; DIARRHEA; DISEASE; METRONIDAZOLE; MANAGEMENT; CARE;
D O I
10.1093/cid/ciu107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade. Although patients respond well to medical therapy such as vancomycin, 20%-30% of patients treated suffer a recurrence of CDI. Methods. We developed a simple/practical scoring rule (logistic regression model) for recurrent CDI using data from 2 large phase 3 clinical trials. Seventy-seven baseline CDI factors were classified: demographics, comorbidity, medications, vital signs, laboratory tests, severity, and symptoms. Predictors with the highest discrimination in each class (using receiver operating characteristics curve) were selected. For the final model, stepwise selection was performed. Discrimination, calibration, and internal validation were used to assess the model. Results. The final model with a simple scoring rule was developed. It includes 4 independent risk factors that are readily available when the patient makes initial contact: age (<75 vs >= 75 years), number of unformed bowel movements during previous 24 hours (<10 vs >= 10), serum creatinine leves (< 1.2 mg/dL vs >= 1.2 mg/dL) and prior episode of CDI (yes vs no). In addition, the model includes choice of treatment (vancomycin or fidaxomicin). Conclusions. The prediction model for recurrence may be useful for treatment decision.
引用
收藏
页码:1386 / 1393
页数:8
相关论文
共 50 条
  • [21] Risk Factors Associated with Recurrent Clostridioides difficile Infection
    Negrut, Nicoleta
    Bungau, Simona
    Behl, Tapan
    Khan, Shamim Ahmad
    Vesa, Cosmin Mihai
    Bustea, Cristiana
    Nistor-Cseppento, Delia Carmen
    Rus, Marius
    Pavel, Flavia-Maria
    Tit, Delia Mirela
    HEALTHCARE, 2020, 8 (03)
  • [22] Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis
    Deshpande, Abhishek
    Pasupuleti, Vinay
    Thota, Priyaleela
    Pant, Chaitanya
    Rolston, David D. K.
    Hernandez, Adrian V.
    Donskey, Curtis J.
    Fraser, Thomas G.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2015, 36 (04) : 452 - 460
  • [23] Risk Factors and Management of Refractory or Recurrent Clostridium difficile Infection in Ileal Pouch Patients
    Seril, Darren N.
    Ashburn, Jean H.
    Lian, Lei
    Shen, Bo
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : 2226 - 2233
  • [24] An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
    Blanco, Natalia
    Foxman, Betsy
    Malani, Anurag N.
    Zhang, Min
    Walk, Seth
    Rickard, Alexander H.
    Eisenberg, Marisa C.
    PLOS ONE, 2017, 12 (08):
  • [25] Clinical Predictors and Risk Factors for Relapsing Clostridium difficile Infection
    Cadena, Jose
    Thompson, George R., III
    Patterson, Jan E.
    Nakashima, Brandy
    Owens, Aaron
    Echevarria, Kelly
    Mortensen, Eric M.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2010, 339 (04) : 350 - 355
  • [26] First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis
    Larrainzar-Coghen, T.
    Rodriguez-Pardo, D.
    Puig-Asensio, M.
    Rodriguez, V.
    Ferrer, C.
    Bartolome, R.
    Pigrau, C.
    Fernandez-Hidalgo, N.
    Pumarola, T.
    Almirante, B.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (03) : 371 - 378
  • [27] Predicting a complicated course of Clostridium difficile infection at the bedside
    Hensgens, M. P. M.
    Dekkers, O. M.
    Goorhuis, A.
    LeCessie, S.
    Kuijper, E. J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (05) : O301 - O308
  • [28] Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection
    Tieu, Jennifer D.
    Williams, Riley J., II
    Skrepnek, Grant H.
    Gentry, Chris A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 220 - 228
  • [29] Clostridium difficile infection: current perspectives
    Janka, Jacqueline
    O'Grady, Naomi R.
    CURRENT OPINION IN CRITICAL CARE, 2009, 15 (02) : 149 - 153
  • [30] Management of Primary and Recurrent Clostridium difficile Infection: An Update
    Chai, Jocelyn
    Lee, Christine H.
    ANTIBIOTICS-BASEL, 2018, 7 (03):